GleamWall
中文EN

SNTI Senti Biosciences Holdings, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1854270 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY51.2%
Revenue 3-yr CAGR-69.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-67,652.7%
Net margin-58,140.5%
FCF margin—
EBITDA margin-63,736.5%

Returns

ROE—
ROA-106.2%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets133.9%
Debt / equity—
Current ratio0.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-19.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$22,000$0
R&D expense$37.59M$34.36M
SG&A expense$26.16M$26.37M
Operating income-$68.78M-$61.04M
Income tax$0$0
Net income-$61.44M-$52.79M
EBITDA-$65.14M-$57.20M
EPS (basic)-2.73-12.03
EPS (diluted)-2.73-12.03
Weighted avg. shares (diluted)22.48M4.60M
Balance sheet
Cash & equivalents$16.42M$51.81M
Current assets$23.27M$58.96M
PP&E, net$12.89M$21.29M
Total assets$51.22M$97.84M
Current liabilities$13.97M$13.15M
Total liabilities$45.63M$47.09M
Shareholders' equity$5.59M$25.65M
Shares outstanding30.88M4.83M
Cash flow statement
Operating cash flow-$43.44M-$41.40M
Capital expenditure$196,000$26,000
Free cash flow-$43.64M-$41.42M
Investing cash flow-$184,000$34,000
Financing cash flow$11.76M$53.73M
Depreciation & amortization$3.64M$3.84M
Stock-based compensation$5.71M$1.75M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.